We are live on ! Find out more
LC

Lunate Capital Portfolio holdings

AUM $196M
1-Year Est. Return 84.21%
This Fund
S&P 500
This Quarter Est. Return
+13.83%
1 Year Est. Return
+84.21%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
+$75.6M
Cap. Flow
+$61.3M
Cap. Flow %
31.27%
Top 10 Hldgs %
100%
Holding
12
New
6
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
BIRK icon
Birkenstock
BIRK
+$40.8M
2
BXSL icon
Blackstone Secured Lending
BXSL
+$23.9M
3
GSBD icon
Goldman Sachs BDC
GSBD
+$20.4M
4
MSDL icon
Morgan Stanley Direct Lending Fund
MSDL
+$16.7M
5
OBDC icon
Blue Owl Capital
OBDC
+$13.4M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$53.4M
2
RVMDW icon
Revolution Medicines Inc Warrant
RVMDW
+$806K

Sector Composition

Rank Sector Weight
1 Financials 37.88%
2 Technology 24.86%
3 Consumer Discretionary 22.17%
4 Real Estate 13.24%
5 Healthcare 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAIL
1
SailPoint Inc
SAIL
$9.17B
$43.9M 22.41%
3,000,000
– –
BIRK icon
2
Birkenstock
BIRK
$7.45B
$43.5M 22.17%
+1,010,000
New +$40.8M
LINE
3
Lineage Inc
LINE
$9.76B
$25.9M 13.24%
600,000
– –
BXSL icon
4
Blackstone Secured Lending
BXSL
$5.39B
$23.7M 12.11%
+1,000,818
New +$23.9M
GSBD icon
5
Goldman Sachs BDC
GSBD
$975M
$20.8M 10.6%
+2,192,392
New +$20.4M
MSDL icon
6
Morgan Stanley Direct Lending Fund
MSDL
$1.26B
$16.7M 8.51%
+1,103,814
New +$16.7M
OBDC icon
7
Blue Owl Capital
OBDC
$5.36B
$13M 6.66%
+1,200,244
New +$13.4M
NAVN
8
Navan Inc
NAVN
$6.79B
$4.57M 2.33%
200,000
– –
NMRA icon
9
Neumora Therapeutics
NMRA
$306M
$3.61M 1.84%
2,124,143
– –
FIG
10
Figma
FIG
$12.6B
$240K 0.12%
+13,290
New +$267K
RVMD icon
11
Revolution Medicines
RVMD
$40.9B
– –
-549,050
Closed -$53.4M
RVMDW icon
12
Revolution Medicines Inc Warrant
RVMDW
$109M
– –
-450,000
Closed -$806K

Similar funds

NWA
Navis Wealth Advisors Rye Brook, New York $196M AUM 33.05% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
LWA
Legacy Wealth Advisors Miami, Florida $196M AUM
CCP
Cyrus Capital Partners New York $196M AUM 123.68% 1-Year Est. Return
PAM
Peninsula Asset Management Bradenton, Florida $196M AUM 10.62% 1-Year Est. Return
MAMF
Mirabaud Asset Management (France) Paris, France $196M AUM
DWG
Darden Wealth Group Ann Arbor, Michigan $196M AUM 48.82% 1-Year Est. Return
CPRPA
Cerity Partners Retirement Plan Advisors New York $196M AUM

Lunate Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Lunate Capital held 12 positions worth $196M, up 63% from $120M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Lunate Capital deployed $61.3M of net new capital in Q2 2026, opening 6 new positions. Its largest new stake was Birkenstock: 1,010,000 shares worth $43.5M.

By sector, the portfolio is most concentrated in Financials at 38% of assets, followed by Technology and Consumer Discretionary.

On the sell side, the most notable exit was Revolution Medicines, an estimated $53.4M sold.

  • Lunate Capital's largest Q2 2026 buy was Birkenstock: 1,010,000 shares worth $43.5M.
  • Lunate Capital fully exited Revolution Medicines in Q2 2026, selling an estimated $53.4M.
  • Lunate Capital's ten largest holdings make up 100% of its $196M portfolio in Q2 2026.
  • Lunate Capital opened 6 new positions and closed 2 in Q2 2026.
  • Lunate Capital's portfolio value rose 63% quarter-over-quarter to $196M.

Based on Lunate Capital's 13F filing for Q2 2026, filed 23 Jul 2026.